Aerpio Therapeutics Initiates Phase 1a Study of AKB-4924, a First in Class Once-Daily, Orally Administered HIF-1 Stabilizer, in Development to Treat Inflammatory Bowel Disease (IBD)

CINCINNATI--(BUSINESS WIRE)--Aerpio Therapeutics, Inc., today announced that it has dosed the first subject in a Phase 1a clinical trial evaluating its product candidate AKB-4924 for the treatment of IBD. This novel, orally administered agent that stabilizes hypoxia inducible factor 1 alpha (HIF-1α), a cellular protein which plays a crucial role in the resolution of inflammation and maintenance of epithelial barrier integrity. In multiple in vivo preclinical models of IBD, AKB-4924 has been sho

Full Story →